Trial · NCT07888621
Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma
NCT07888621, Phase 2, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma. Trials, record NCT07888621. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07888621
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma
- NCT number
- NCT07888621
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Conditions
- PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)
- Interventions
- Glofitamab, Gemcitabine, Oxaliplatin, ASCT or whole-brain radiotherapy (WBRT), Obinutuzumab
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | Assessed after Cycle 3 (Week 9) and after Cycle 6 (Week 18); each cycle is 21 days. Non-responders discontinue; responders are assessed through maintenance, up to approximately Week 36 (longer if ASCT or WBRT is interposed). | |
| Secondary | Complete Response Rate (CRR) | Assessed after Cycle 3 (Week 9) and after Cycle 6 (Week 18); each cycle is 21 days. Non-responders discontinue; responders are assessed through maintenance, up to approximately Week 36 (longer if ASCT or WBRT is interposed). | |
| Secondary | 1-Year Progression-Free Survival (PFS) Rate | Efficacy assessed every 3 months during the first year; follow-up for 1 year from first dose. | |
| Secondary | 1-Year Overall Survival (OS) Rate | Follow-up every 3 months during the first year and every 6 months during the second year; follow-up for 1 year from first dose. | |
| Secondary | Incidence of Adverse Events and Serious Adverse Events | From first dose until at least 30 days after the last dose (AEs followed until resolution or stabilisation); weekly safety follow-up during treatment and every 3 months during long-term follow-up up to 2 years. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07888621
GET https://conductscience.org/api/trials/v1/NCT07888621/registered